Filter
4403
Filtered Results: 4403
Text search:
drug
therapy
Featured
Recommendations
405
New Publications
1125
Language
Document type
No document type
2773
Studies & Reports
608
Guidelines
585
Manuals
168
Strategic & Response Plan
100
Fact sheets
68
Training Material
51
Situation Updates
18
Infographics
13
Resource Platforms
9
Brochures
7
Online Courses
2
App
1
Countries / Regions
India
288
Kenya
124
Global
119
South Africa
116
Uganda
96
Ethiopia
94
Western and Central Europe
93
Nigeria
83
Tanzania
82
Nepal
77
Zambia
76
Sierra Leone
63
Malawi
62
Eastern Europe
58
Liberia
55
Ghana
53
Africa
53
Latin America and the Carribbean
53
Ukraine
52
Rwanda
50
Myanmar / Burma
50
Bangladesh
41
Namibia
41
Zimbabwe
37
Asia
36
Russia
36
Indonesia
35
Lesotho
33
Philippines
32
Cambodia
26
South–East Asia Region
23
Botswana
20
Senegal
19
Germany
17
Syria
16
Eswatini/ Swaziland
16
Burkina Faso
14
Mozambique
14
East and Southern Africa
13
USA
12
Albania
11
West and Central Africa
11
Middle East and North Africa
11
Brazil
11
Colombia
10
Cameroon
10
Haiti
10
Congo, Democratic Republic of
10
South Sudan
10
Tajikistan
9
Eastern Europe and Central Asia
9
Venezuela
8
Thailand
7
Sudan
7
Pakistan
7
Benin
6
Western Pacific Region
6
Argentina
6
Georgia
6
China
5
Afghanistan
5
Peru
5
Armenia
5
Iraq
5
North Macedonia
4
Guinea
4
Paraguay
4
United Kingdom
4
Spain
4
Bolivia
4
Vietnam
4
Moldova
4
Yemen
4
Bhutan
4
Timor Leste/ East Timor
3
Laos
3
Estonia
3
Jordan
3
Jamaica
3
Sri Lanka
3
Somalia
3
Switzerland
2
Turkey
2
Kazakhstan
2
Iran
2
Canada
2
Fiji
2
Kyrgyzstan
2
Saudi Arabia
2
North America
2
Gabon
2
Lebanon
2
Papua New Guinea
2
Central African Republic
2
Poland
2
Angola
2
North Korea
1
Mexico
1
Serbia
1
Australia
1
Gambia
1
Chile
1
Singapore
1
Uzbekistan
1
Malaysia
1
Austria
1
Morocco
1
Mongolia
1
Qatar
1
Bulgaria
1
Hungary
1
Lithuania
1
Ireland
1
Turkmenistan
1
Denmark
1
Belgium
1
France
1
Maldives
1
Mauritius
1
Tunisia
1
Portugal
1
Belarus
1
Southern Africa
1
Côte d’Ivoire / Ivory Coast
1
Romania
1
Greece
1
Palestine
1
Mali
1
Chad
1
Libya
1
Ecuador
1
Solomon Islands
1
Madagascar
1
Authors & Publishers
Publication Years
Category
Countries
1675
Clinical Guidelines
462
Public Health
199
Women & Child Health
147
Key Resources
87
Capacity Building
59
Pharmacy & Technologies
47
Toolboxes
HIV
641
TB
483
Mental Health
440
AMR
225
NTDs
169
Pharmacy
150
COVID-19
149
NCDs
105
Caregiver
80
Rapid Response
57
Ebola & Marburg
56
Refugee
46
Conflict
42
Disability
41
Planetary Health
28
Global Health Education
26
Polio
17
Health Financing Toolbox
15
Cholera
13
Specific Hazards
11
Natural Hazards
10
Zika
9
Social Ethics
6
Q12: Should the treatment be similar in individuals with intellectual disability and epilepsy compared to people with epilepsy only?
BMJ Global Health, Vol. 4 (2019) no.2
Antibiotic resistance is threatening global health, development and food security; however, measures for assessing and communicating the threat of resistance are lacking. The Drug Resistance Index (DRI) allows for global assessment of the relative efficacy of ...
Antimalarial drug resistance has emerged as a threat to global malaria control efforts, particularly in the Greater Mekong subregion. Drawing on data collected through more than 1000 therapeutic efficacy studies as well as molecular marker studies of Plasmodium falciparum drug resistance, the Report...
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ...
The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO.
Pretreatment HIVDR to non-nucleoside reverse-transcriptase inhibitors (NNRTI) can affect more than 10% of adults starting therapy and is fo...
This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws o...
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...
Preventing tuberculosis infection from progressing to tuberculosis disease is a crucial component of the goal to eliminate tuberculosis. When deciding on the use of tuberculosis preventive therapy among household contacts, policy makers regularly ask questions, such as whether tuberculosis preventiv...
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi...
Chagas disease affects 8-10 million people worldwide, mainly in Latin America. The current therapy for Chagas disease is limited to nifurtimox and benznidazole, which are effective in treating only the acute phase of the disease but with severe side effects. Therefore, there is an unmet need for new...
The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public health problem throughout Latin America. Current therapeutic options are characterised by limited efficacy, long treatment regimens and frequent toxic side-effects. Advances in this area have been compromised by gaps...
DOI: 10.5772/intechopen.102891Little progress has been made since the 1960s and 19. 70s to widen the therapeutic arsenal against Trypanosoma cruzi, the causative pathogen of Chagas disease, which remains a frustrating and perplexing infectious disease. This chapter focuses on the strategic and opera...
The Strategy to respond to antimalarial drug resistance in Africa is a technical and advocacy document, grounded in the best available evidence to date and aimed at minimizing the threat and impact of antimalarial drug resistance of Plasmodium falciparum parasites in Africa. Its objectives are to: i...
Effective malaria case management requires quick access to diagnostics and antimalarial treatments to reduce illness and death. Artemisinin-based combination therapy (ACT) has been essential to malaria treatment since 2001, as it combines artemisinin for rapid parasite reduction with a partner drug ...
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...
1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization
The pamphlet "Oxycodone" provides an overview of the opioid drug class, explaining its uses, effects, and risks. It describes positive effects like euphoria and pain relief, alongside negative effects such as respiratory depression, confusion, and constipation. Withdrawal symptoms include anxiety, i...
Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on
dolutegravir-based antiretroviral therapy (November 2020– September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 ...
